Wilms' TumorNCT05179850
Computer Aided Diagnostic Tool on Computed Tomography Images for Diagnosis of Retroperitoneal Tumor in Children
An observational study of Wilms' Tumor and Neuroblastoma, run by West China Hospital at 1 site in China.
Trial summary
The aim of this study was to evaluate the diagnostic efficacy of computer aided diagnostic tool for retroperitoneal tumor using machine learning and deep learning techniques on computed tomography images in children. Read more about this study
- Who is it for?
- Ages 0 to 18 years
- Conditions the study is for
- Wilms' Tumor, Neuroblastoma, Teratoma
- What is being tested?
- Radiomic Algorithm
- How many people
- 400 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2021to 31 Dec 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 0 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Patients who had retroperitoneal tumor and completed the abdominal computed tomography examination before operation, biopsy, neoadjuvant chemotherapy, and radiotherapy.
Who may be able to join
- Age up to 18 years old
- Receiving no treatment before diagnosis
- With written informed consent
Who cannot join
- Clinical data missing
- Unavailable computed tomography images
- Without written informed consent
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, 6100041
Yuhan Yang, MD, 8613258389785, yyh_1023@163.com
Yuhan Yang, MD
About this study
The aim of this study was to evaluate the diagnostic efficacy of computer aided diagnostic tool for retroperitoneal tumor using machine learning and deep learning techniques on computed tomography images in children.
Read the detailed description
The retroperitoneal space extends from the lumbar region to the pelvic region and houses vital structures such as the kidney, the ureter, the adrenal glands, the pancreas, the aorta and its branches, the inferior vena cava and its tributaries, lymph nodes, and loose connective tissue meshwork along with fat. This space thus allows the silent growth of primary and metastatic tumors, such that clinical features appear often too late. The therapeutic regimen differs on various types of retroperitoneal tumor in children. It is damaging for pediatric patients to acquire histological specimens through invasive procedures. Hence, an urgent evaluation is absolutely necessary for preoperative diagnosis in such cases via noninvasive approaches. This study is a retrospective-prospective design by West China Hospital, Sichuan University, including clinical data and radiological images. A retrospective database was enrolled for patients with definite histological diagnosis and available computed tomography images from June 2010 and December 2020. The investigators have constructed deep learning and machine learning radiomics diagnostic models on this retrospective cohort and validated it internally. A prospective cohort would recruit infantile patients diagnosed as retroperitoneal tumor since January 2021. The proposed deep learning model would also be validated in this prospective cohort externally. The aim of this study was to evaluate the diagnostic efficacy of computer aided diagnostic tool for retroperitoneal tumor using machine learning and deep learning techniques on computed tomography images in children.
- Conditions
- Wilms' Tumor, Neuroblastoma, Teratoma, Lymphoma, Sarcoma, Germ Cell Tumor
- Being tested
- Radiomic Algorithm
- Medical subject headings
- Wilms Tumor, Neuroblastoma, Teratoma, Lymphoma, Sarcoma, Neoplasms, Germ Cell and Embryonal
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Radiomic AlgorithmDiagnostic test
Different radiomic, machine learning, and deep learning strategies for radiomic features extraction, sorting features and model constriction.
| Study group | Role | What they receive |
|---|---|---|
| Retrospective cohort | The internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort. Receives: Diagnostic Test: Radiomic Algorithm | |
| Prospective cohort | The same inclusion/exclusion criteria were applied for the same center prospectively. It is a external validation cohort. Receives: Diagnostic Test: Radiomic Algorithm |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pathological tumor diagnosis
The diagnosis is defined by histopathological specimens from surgery and/or biopsy.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jan 2022
- Study start1 Jan 2021
- Primary completion31 Dec 2023 (estimated)
- Study completion31 Dec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Wilms' TumorStudies of the same condition, open and under way.
- More trials run by West China HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- West China Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yuhan Yang, West China Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05179850
- Sponsor's protocol ID
- HX-2021477
- Status last verified
- Jan 2022
- First submitted
- 16 Dec 2021
- Last updated
- 20 Jan 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Jan 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Computer Aided Diagnostic Tool on Computed Tomography Images for Diagnosis of Retroperitoneal Tumor in Children
- ClinicalTrials.gov ID
- NCT05179850
- Acronym / sponsor ID
- HX-2021477
- Conditions
- Wilms' Tumor, Neuroblastoma, Teratoma, Lymphoma, Sarcoma, Germ Cell Tumor
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- West China HospitalUniversity, hospital or other
- Study start
- 1 Jan 2021 (actual)
- Primary completion
- 31 Dec 2023 (estimated)
- Study completion
- 31 Dec 2023 (estimated)
- First posted
- 5 Jan 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study was to evaluate the diagnostic efficacy of computer aided diagnostic tool for retroperitoneal tumor using machine learning and deep learning techniques on computed tomography images in children.
Detailed description
The retroperitoneal space extends from the lumbar region to the pelvic region and houses vital structures such as the kidney, the ureter, the adrenal glands, the pancreas, the aorta and its branches, the inferior vena cava and its tributaries, lymph nodes, and loose connective tissue meshwork along with fat. This space thus allows the silent growth of primary and metastatic tumors, such that clinical features appear often too late. The therapeutic regimen differs on various types of retroperitoneal tumor in children. It is damaging for pediatric patients to acquire histological specimens through invasive procedures. Hence, an urgent evaluation is absolutely necessary for preoperative diagnosis in such cases via noninvasive approaches. This study is a retrospective-prospective design by West China Hospital, Sichuan University, including clinical data and radiological images. A retrospective database was enrolled for patients with definite histological diagnosis and available computed tomography images from June 2010 and December 2020. The investigators have constructed deep learning and machine learning radiomics diagnostic models on this retrospective cohort and validated it internally. A prospective cohort would recruit infantile patients diagnosed as retroperitoneal tumor since January 2021. The proposed deep learning model would also be validated in this prospective cohort externally. The aim of this study was to evaluate the diagnostic efficacy of computer aided diagnostic tool for retroperitoneal tumor using machine learning and deep learning techniques on computed tomography images in children.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Retrospective cohort | – | Diagnostic Test: Radiomic AlgorithmThe internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort. |
| Prospective cohort | – | Diagnostic Test: Radiomic AlgorithmThe same inclusion/exclusion criteria were applied for the same center prospectively. It is a external validation cohort. |
Who may qualify
- Ages
- 0 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Patients who had retroperitoneal tumor and completed the abdominal computed tomography examination before operation, biopsy, neoadjuvant chemotherapy, and radiotherapy.
Key inclusion criteria (3 listed)
- Age up to 18 years old
- Receiving no treatment before diagnosis
- With written informed consent
Key exclusion criteria (3 listed)
- Clinical data missing
- Unavailable computed tomography images
- Without written informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Radiomic AlgorithmDifferent radiomic, machine learning, and deep learning strategies for radiomic features extraction, sorting features and model constriction. | Diagnostic test | Prospective cohort, Retrospective cohort |
Primary outcome
Pathological tumor diagnosis
Time frame: Baseline
The diagnosis is defined by histopathological specimens from surgery and/or biopsy.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jan 2022.
- Individual participant dataSharing planned: No
Related trials for Wilms' Tumor
RecruitingObservational study
International PPB/DICER1 Registry
Pleuropulmonary Blastoma, Sertoli-Leydig Cell Tumor
RecruitingPhase 2
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Wilms Tumor, Rhabdoid Tumor
Active, not recruitingPhase 2
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
RecruitingPhase 1
Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT)
DMG, DIPG
Active, not recruitingPhase 2
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Wilms' Tumor and Neuroblastoma, run by West China Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 20 Jan 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Yuhan Yang, MD (8613258389785, yyh_1023@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pathological tumor diagnosis (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2022.